Assessment of ocular hypotensive effect and safety 12 months after changing from an unfixed combination to a latanoprost 0.005% + timolol maleate 0.5% fixed combination

Kenji Inoue1, Ryoko Okayama1, Risako Higa1, Masato Wakakura1, Goji Tomita21Inouye Eye Hospital, 4-3 Kanda-Surugadai, Chiyoda-ku, 2Second Department of Ophthalmology, Toho University School of Medicine, Meguro-ku, Tokyo, JapanBackground: Latanoprost 0.005% + timolol maleate 0.5% combined eyedrops wer...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Inoue K, Okayama R, Higa R, Wakakura M, Tomita G
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/375540b7f3a7485693654dd365eabf31
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:375540b7f3a7485693654dd365eabf31
record_format	dspace
spelling	oai:doaj.org-article:375540b7f3a7485693654dd365eabf312021-12-02T07:57:35ZAssessment of ocular hypotensive effect and safety 12 months after changing from an unfixed combination to a latanoprost 0.005% + timolol maleate 0.5% fixed combination1177-54671177-5483https://doaj.org/article/375540b7f3a7485693654dd365eabf312012-04-01T00:00:00Zhttp://www.dovepress.com/assessment-of-ocular-hypotensive-effect-and-safety-12-months-after-cha-a9727https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Kenji Inoue1, Ryoko Okayama1, Risako Higa1, Masato Wakakura1, Goji Tomita21Inouye Eye Hospital, 4-3 Kanda-Surugadai, Chiyoda-ku, 2Second Department of Ophthalmology, Toho University School of Medicine, Meguro-ku, Tokyo, JapanBackground: Latanoprost 0.005% + timolol maleate 0.5% combined eyedrops were recently made available in Japan. We prospectively investigated the intraocular pressure (IOP)-lowering effect, visual preservation effect, and adverse reactions of a one-year administration of this fixed combination.Methods: The subjects included 162 eyes from 162 patients diagnosed with either primary open-angle glaucoma or ocular hypertension and using an unfixed combination of latanoprost 0.005% and timolol maleate 0.5%. The unfixed combination was discontinued and replaced with the latanoprost 0.005% + timolol maleate 0.5% fixed combination with no washout period. IOP was measured before (baseline) and 3, 6, 9, and 12 months after the change. The mean deviation value of Humphrey field analysis was compared. Adverse reactions were examined at every follow-up.Results: No significant differences were found between mean IOP values obtained at baseline (mean &plusmn; standard deviation, 15.2 &plusmn; 3.3 mmHg) 3 months (15.1 &plusmn; 3.2 mmHg), 6 months (15.3 &plusmn; 3.1 mmHg), 9 months (15.3 &plusmn; 3.1 mmHg), and 12 months (15.1 &plusmn; 3.2 mmHg) after the change from the unfixed to the fixed combination of eyedrops (P = 0.212). In addition, no significant differences were observed between mean deviation values obtained at baseline (&ndash;9.11 &plusmn; 6.94 dB) and 12 months (&ndash;10.08 &plusmn; 7.24 dB) after the change (P = 0.114). Thirty-one patients discontinued the fixed combination within 12 months of replacement, due to an insufficient IOP decrease (20 patients, 12.3%) and adverse reactions (11 patients, 6.8%).Conclusion: Following replacement of two eyedrop medications (latanoprost 0.005% and timolol maleate 0.5%) by one fixed combination (latanoprost 0.005% + timolol maleate 0.5%), IOP and visual field were preserved. However, 20% of the patients discontinued the new treatment because of an insufficient IOP decrease and complaints of adverse reactions.Keywords: latanoprost 0.005%, timolol maleate 0.5%, fixed combination, intraocular pressure, safety, visual fieldInoue KOkayama RHiga RWakakura MTomita GDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2012, Iss default, Pp 607-612 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Inoue K Okayama R Higa R Wakakura M Tomita G Assessment of ocular hypotensive effect and safety 12 months after changing from an unfixed combination to a latanoprost 0.005% + timolol maleate 0.5% fixed combination
description	Kenji Inoue1, Ryoko Okayama1, Risako Higa1, Masato Wakakura1, Goji Tomita21Inouye Eye Hospital, 4-3 Kanda-Surugadai, Chiyoda-ku, 2Second Department of Ophthalmology, Toho University School of Medicine, Meguro-ku, Tokyo, JapanBackground: Latanoprost 0.005% + timolol maleate 0.5% combined eyedrops were recently made available in Japan. We prospectively investigated the intraocular pressure (IOP)-lowering effect, visual preservation effect, and adverse reactions of a one-year administration of this fixed combination.Methods: The subjects included 162 eyes from 162 patients diagnosed with either primary open-angle glaucoma or ocular hypertension and using an unfixed combination of latanoprost 0.005% and timolol maleate 0.5%. The unfixed combination was discontinued and replaced with the latanoprost 0.005% + timolol maleate 0.5% fixed combination with no washout period. IOP was measured before (baseline) and 3, 6, 9, and 12 months after the change. The mean deviation value of Humphrey field analysis was compared. Adverse reactions were examined at every follow-up.Results: No significant differences were found between mean IOP values obtained at baseline (mean &plusmn; standard deviation, 15.2 &plusmn; 3.3 mmHg) 3 months (15.1 &plusmn; 3.2 mmHg), 6 months (15.3 &plusmn; 3.1 mmHg), 9 months (15.3 &plusmn; 3.1 mmHg), and 12 months (15.1 &plusmn; 3.2 mmHg) after the change from the unfixed to the fixed combination of eyedrops (P = 0.212). In addition, no significant differences were observed between mean deviation values obtained at baseline (&ndash;9.11 &plusmn; 6.94 dB) and 12 months (&ndash;10.08 &plusmn; 7.24 dB) after the change (P = 0.114). Thirty-one patients discontinued the fixed combination within 12 months of replacement, due to an insufficient IOP decrease (20 patients, 12.3%) and adverse reactions (11 patients, 6.8%).Conclusion: Following replacement of two eyedrop medications (latanoprost 0.005% and timolol maleate 0.5%) by one fixed combination (latanoprost 0.005% + timolol maleate 0.5%), IOP and visual field were preserved. However, 20% of the patients discontinued the new treatment because of an insufficient IOP decrease and complaints of adverse reactions.Keywords: latanoprost 0.005%, timolol maleate 0.5%, fixed combination, intraocular pressure, safety, visual field
format	article
author	Inoue K Okayama R Higa R Wakakura M Tomita G
author_facet	Inoue K Okayama R Higa R Wakakura M Tomita G
author_sort	Inoue K
title	Assessment of ocular hypotensive effect and safety 12 months after changing from an unfixed combination to a latanoprost 0.005% + timolol maleate 0.5% fixed combination
title_short	Assessment of ocular hypotensive effect and safety 12 months after changing from an unfixed combination to a latanoprost 0.005% + timolol maleate 0.5% fixed combination
title_full	Assessment of ocular hypotensive effect and safety 12 months after changing from an unfixed combination to a latanoprost 0.005% + timolol maleate 0.5% fixed combination
title_fullStr	Assessment of ocular hypotensive effect and safety 12 months after changing from an unfixed combination to a latanoprost 0.005% + timolol maleate 0.5% fixed combination
title_full_unstemmed	Assessment of ocular hypotensive effect and safety 12 months after changing from an unfixed combination to a latanoprost 0.005% + timolol maleate 0.5% fixed combination
title_sort	assessment of ocular hypotensive effect and safety 12 months after changing from an unfixed combination to a latanoprost 0.005% + timolol maleate 0.5% fixed combination
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/375540b7f3a7485693654dd365eabf31
work_keys_str_mv	AT inouek assessmentofocularhypotensiveeffectandsafety12monthsafterchangingfromanunfixedcombinationtoalatanoprost0005timololmaleate05fixedcombination AT okayamar assessmentofocularhypotensiveeffectandsafety12monthsafterchangingfromanunfixedcombinationtoalatanoprost0005timololmaleate05fixedcombination AT higar assessmentofocularhypotensiveeffectandsafety12monthsafterchangingfromanunfixedcombinationtoalatanoprost0005timololmaleate05fixedcombination AT wakakuram assessmentofocularhypotensiveeffectandsafety12monthsafterchangingfromanunfixedcombinationtoalatanoprost0005timololmaleate05fixedcombination AT tomitag assessmentofocularhypotensiveeffectandsafety12monthsafterchangingfromanunfixedcombinationtoalatanoprost0005timololmaleate05fixedcombination
_version_	1718399035622031360

Assessment of ocular hypotensive effect and safety 12 months after changing from an unfixed combination to a latanoprost 0.005% + timolol maleate 0.5% fixed combination

Ejemplares similares